Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study

Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study

Background: The development of newer agents, including anti-CD38 monoclonal antibodies (mAbs), has significantly improved overall survival (OS) in patients with relapsed or refractory multiple myeloma (RRMM). However, the treatment of older patients with RRMM who are transplant-ineligible remains ch...

Full description

Saved in:
Bibliographic Details
Main Authors: Satoshi Yamasaki, Michitoshi Hashiguchi, Nao Yoshida-Sakai, Hiroto Jojima, Koichi Osaki, Takashi Okamura, Yutaka Imamura
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Hematology Reports
Subjects:
older patients
multiple myeloma
relapsed or refractory
daratumumab
isatuximab
propensity score matching analysis
Online Access:https://www.mdpi.com/2038-8330/16/4/68
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items